Yazar "Dal, Mehmet Sinan" için listeleme
-
Clinical characteristics and therapeutic outcomes of paroxysmal nocturnal hemoglobinuria patients in Turkey: A multicenter experience
Gören Şahin, Deniz; Akay, Olga Meltem; Keklik, Muzaffer; Okan, Vahap; Karakuş, Abdullah; Demir, Cengiz; Erkurt, Mehmet Ali; İlkkılıç, Kadir; Yıldırım, Rahşan; Akgün Çağlıyan, Gülsüm; Aksu, Salih; Doğu, Mehmet Hilmi; Dal, Mehmet Sinan; Karakuş, Volkan; Gemici, Aliihsan; Terzi, Hatice; Kelkitli, Engin; Şıvgın, Serdar; Ünal, Ali; Yılmaz, Mehmet; Ayyıldız, Orhan; Korkmaz, Serdal; Eser, Bülent; Altuntaş, Fevzi (Springer, 2021)The aim of this study is to collect paroxysmal nocturnal hemoglobinuria (PNH) patient data from hematology centers all over Turkey in order to identify clinical features and management of PNH patients. Patients with PNH ... -
Glofitamab in relapsed/refractory diffuse large B cell lymphoma: Real world data
Ferhanoğlu, Burhan; Gülbaş, Zafer; Uzay, Ant; Özcan, Muhit; Özkalemkaş, Fahir; Dal, Mehmet Sinan; Kalyon, Hakan; Akay, Olga Meltem; Deveci, Burak; Bekoz, Hüseyin; Sevindik, Ömür Gökmen; Toptaş, Tayfur; Yılmaz, Asu Fergün; Koyun, Derya; Alkış, Nihan; Birtaş Ateşoğlu, Elif (American Society of Hematology, 2022)Abstract INTRODUCT ̇ION Glofitamab is a T-cell-engaging bispecific antibody connecting CD20 on B cells and CD3 on T cells. Although, most of the patients with B-cell non-Hodgkin lymphoma (BNHL) achieve complete response ... -
Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data
Birtaş Ateşoğlu, Elif; Gülbaş, Zafer; Uzay, Ant; Özcan, Muhit; Özkalemkaş, Fahir; Dal, Mehmet Sinan; Kalyon, Hakan; Akay, Olga Meltem; Ferhanoğlu, Burhan (Wiley, 2023)Glofitamab is a CD3xCD20 bi-specific antibody with two fragments directed to the CD20 antigen and a single CD3-binding fragment. Encouraging response and survival rates were recently reported in a pivotal phase II expansion ... -
Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: A real-world data from Turkey
Dal, Mehmet Sinan; Ulu, Bahar Uncu; Uzay, Ant; Akay, Olga Meltem; Beşışık, Sevgi; Yenerel, Mustafa Nuri; Çelik, Serhat; Kaynar, Leylagül; Yücel, Orhan Kemal; Deveci, Burak; Sönmez, Mehmet; Mehtap, Özgür; Beköz, Hüseyin Saffet; Sunu, Cenk; Salim, Ozan; Ulaş, Turgay; Kartı, Sami; Altuntaş, Fevzi; Ferhanoğlu, Burhan; Tuğlular, Tülin Fırat (Springer, 2023)Polatuzumab vedotin (Pola) with bendamustine and rituximab (BR) is a promising option for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We analyzed the data of 71 R/R DLBCL patients who had ...